Harmony Biosciences Says New Data Supports Neurology Pipeline

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) shares closed higher by around 8% on Tuesday following the company's announcement of record revenue for the second quarter of 2026.

The neurological disease-focused pharma company reported second quarter earnings of $1.28 per share, beating the consensus of 94 cents.

Read Also: Twist Bioscience Sees AI Drug Discovery Pipeline Expand Sales reached $261.30 million, surpassing the consensus of $248.41 million.

Harmony Biosciences (HRMY) Surges On Record Q2 Revenue And WAKIX Growth In its latest earnings report, Harmony Biosciences revealed that net revenue for WAKIX grew 30% year-over-year to $261.3 million, with an estimated average of 8,950 patients using the product.

The company reiterated its full-year guidance for WAKIX net revenue, projecting between $1.0 billion and $1.04 billion compared to the consensus of $1.02 billion.

The company also announced single ascending dose (SAD) data from its Phase 1 study of BP-205, demonstrating favorable pharmacokinetic (PK) and safety/tolerability profiles.

The data support Harmony's robust orexin development strategy, including initiating Phase 2 studies beginning in mid-2027 to evaluate multiple CNS indications.

HRMY Technical Outlook: Momentum Builds Toward Resistance The stock is currently trading at $39.07, which is 9.1% above its 20-day simple moving average (SMA) of $35.77 and 13% above its 50-day SMA of $34.56.

The moving average convergence divergence (MACD) is above its signal line, indicating that downside pressure is easing and momentum is improving compared to previous trends.

With the stock price approaching key resistance at $41.00, traders should watch for potential breakout opportunities.

The stock's recent performance has also seen it gain about 9.88% over the past 12 months, suggesting a positive longer-term trend.

Analyst Consensus & Recent Actions: The stock carries a Hold rating with an average price forecast of $39.86.

Recent analyst moves include: Needham: Buy (Raises Price Forecast to $50 (Aug 4) Mizuho: Outperform (Raises Forecast to $51.00) (July 31) HC Wainwright & Co.: Buy (Maintains Forecast to $55.00) (July 16) Deutsche Bank: Hold (Raises Forecast to $36.00) (June 30) HRMY Value, Quality And Momentum Versus The Market Below is the Edge scorecard for Harmony Biosciences Holdings, highlighting its strengths and weaknesses compared to the broader market: Value: 82.66 — Indicates a strong value opportunity relative to peers.

Quality: 78.62 — Suggests a healthy balance sheet and operational efficiency.

Momentum: 35.33 — Reflects weaker momentum compared to the broader market.

HRMY Stock Price Activity: Harmony Biosciences shares were up 0.26% at $38.88 during premarket trading on Wednesday, according to Pro data.

Read Also: Chamath Palihapitiya Says AI Agents Will Undermine 'Bottoms Up' Software Strategy Amid 'IP/Alpha Leakage' Concerns Image via Shutterstock